ACADIA Pharmaceuticals Inc.  

(Public, NASDAQ:ACAD)   Watch this stock  
Find more results for ACAD
36.32
+0.49 (1.37%)
After Hours: 36.77 +0.45 (1.24%)
Oct 20, 6:18PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 35.33 - 36.54
52 week 20.68 - 41.20
Open 35.85
Vol / Avg. 1.33M/1.41M
Mkt cap 4.45B
P/E     -
Div/yield     -
EPS -2.53
Shares 122.40M
Beta 3.80
Inst. own 102%
Nov 6, 2017
Q3 2017 ACADIA Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Oct 4, 2017
ACADIA Pharmaceuticals Inc Initiates Phase III Study of Pimavanserin in Dementia-Related Psychosis - Call - Webcast
Sep 26, 2017
ACADIA Pharmaceuticals Inc at Ladenburg Thalmann Healthcare Conference - Webcast
Aug 8, 2017
Q2 2017 ACADIA Pharmaceuticals Inc Earnings Call - Webcast
Aug 8, 2017
Q2 2017 ACADIA Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '17) 2016
Net profit margin -221.30% -1565.94%
Operating margin -224.56% -1574.14%
EBITD margin - -1563.60%
Return on average assets -56.39% -69.32%
Return on average equity -62.00% -75.58%
Employees 420 -
CDP Score - -

Address

3611 Valley Centre Dr Ste 300
SAN DIEGO, CA 92130-3331
United States - Map
+1-858-5582871 (Phone)
+1-858-5582872 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

ACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PD Psychosis). NUPLAZID is a selective serotonin inverse agonist (SSIA), preferentially targeting 5-HT2A receptors. The Company is conducting a Phase II trial, referred to as the SERENE Study, designed to examine the efficacy and safety of pimavanserin as a treatment for Alzheimer's disease (AD) Agitation. It is also conducting a Phase III, six-week, randomized, double-blind, placebo-controlled, multi-center, outpatient study, referred to as the ENHANCE-1 study, designed to examine the use of pimavanserin in patients with schizophrenia.

Officers and directors

Stephen R. Biggar M.D. Ph.D. Chairman of the Board
Age: 46
Bio & Compensation  - Reuters
Stephen R. Davis President, Chief Executive Officer, Director
Age: 56
Bio & Compensation  - Reuters
Todd S. Young Executive Vice President, Chief Financial Officer
Age: 45
Bio & Compensation  - Reuters
Glenn F. Baity Executive Vice President, General Counsel, Secretary
Age: 47
Bio & Compensation  - Reuters
Srdjan Stankovic M.D. Executive Vice President, Head - Research and Development
Age: 60
Bio & Compensation  - Reuters
Michael J. Yang Executive Vice President, Chief Commercial Officer
Age: 55
Bio & Compensation  - Reuters
Edmund P. Harrigan M.D. Director
Age: 64
Bio & Compensation  - Reuters
Julian C. Baker Independent Director
Age: 50
Bio & Compensation  - Reuters
Laura A. Brege Independent Director
Age: 59
Bio & Compensation  - Reuters
James M. Daly Independent Director
Age: 55
Bio & Compensation  - Reuters